CapeRay Medical

Primary contact

Contact: Natasha Steele
e-Mail: natasha@caperay.com

Secondary contact

Contact: Kit Vaughan
e-Mail: kit@caperay.com

Company details

Key sector/s:
  • Electronics
Tel:+27 (0) 21 702 4299
Fax:+27 (0) 21 702 4299
Postal address:


Unit 2, 51 Bell Crescent Westlake Business Park 7945


Physical address:


Suite 2, 51 Bell Crescent, Westlake Business Park, Cape Town, Western Cape,7945


Website:http://www.caperay.com

Company profile

CapeRay is a privately held company that was spun out from the University of Cape Town (UCT) in early 2010 with an initial investment by the Industrial Development Corporation (IDC) of South Africa. Aside from UCT and the IDC, other shareholders include the two founders Kit Vaughan and Tania Douglas, four original staff members, and an employee share trust.

One woman in eight is diagnosed with breast cancer during her life time, making it the number one killer of women aged 40 to 55. Early detection of tumours enables successful treatment, but mammography – an X-ray of the breast – fails to detect cancer in dense breast tissue. Since 40% of all women have dense breasts, a false negative finding can have devastating consequences: more expensive treatment and a poor prognosis.

CapeRay has developed a breakthrough product: a single  device that acquires dual-modality images – both full-field digital mammography (FFDM) and automated breast ultrasound (ABUS) – simultaneously with the same breast orientation and compression. Aceso, named after the Greek goddess of healing, was successfully tested in a clinical trial of 62 women in November 2015, demonstrating the potential of fusing FFDM and ABUS images. In May 2017 CapeRay was awarded a US Patent (9,636,073) for its dual-modality technology, while in September 2017, its Aceso system was awarded the CE Mark. 

Product & services

CapeRay, which has held the ISO 13485 certification since June 2012, manufactures and sells the Aceso dual-modality system for the early detection of breast cancer.

 

User login

(If you're a human, don't change the following field)
Your first name.

Connect & Share

Favourites Email RSS Feed LinkedIn Facebook Twitter Delicious